RegeneRx Biopharmaceuticals, Inc.

RegeneRx reports net loss of $5.5 million

Published in Cardiovascular Business Week, May 2nd, 2006

RegeneRx Biopharmaceuticals, Inc. (RGN) reported a net loss of $5.5 million or $0.15 per share for the year ended December 31, 2005, compared with a net loss of $3.3 million or $0.10 per share for the year ended December 31, 2004.

For the fourth quarter, the company's net loss was $2.2 million, which included a non-cash charge of $0.6 million for previously capitalized patents costs. The net loss for 2005 resulted primarily from the continued research and development expenditures related to ongoing phase II clinical trials to study the company's product (TB4) for the treatment of chronic dermal wounds, research and development efforts related to its technology platform,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2006-05-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry